Literature DB >> 20920746

Epigenetics and miRNAs in human cancer.

Muller Fabbri1, George A Calin.   

Abstract

Epigenetic factors and microRNAs (miRNAs) are regulators of gene expression. Their regulatory function is frequently aberrant in cancer. In this chapter, we show that a tight connection occurs between miRNAs and epigenetics. Epigenetic factors can be responsible for the aberrancies of the miRNome (defined as the full spectrum of miRNAs for a specific genome) observed in cancer. Indeed, miRNAs undergo the same epigenetic regulatory laws like any other protein-coding gene. Moreover, a specific group of miRNAs (defined as epi-miRNAs) can directly target effectors of the epigenetic machinery (such as DNA methyltransferases, histone deacetylases, and polycomb repressive complex genes) and indirectly affect the expression of tumor suppressor genes, whose expression is controlled by epigenetic factors. The result of this epigenetic-miRNA interaction is a new layer of complexity in gene regulation, whose comprehension opens new avenues to understand human cancerogenesis and to achieve new cancer treatments.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920746     DOI: 10.1016/B978-0-12-380866-0.60004-6

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  66 in total

1.  Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.

Authors:  Edward A Ratovitski
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

2.  Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.

Authors:  Dengyong Zhang; Xiang Ma; Wanliang Sun; Peiyuan Cui; Zheng Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  [Epigentics in rheumatic diseases].

Authors:  A Jüngel; S Gay
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

Review 4.  MicroRNA in intervertebral disc degeneration.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2015-03-04       Impact factor: 6.831

Review 5.  Interplay between the cancer genome and epigenome.

Authors:  Hui Shen; Peter W Laird
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

Review 6.  The lncRNA-MYC regulatory network in cancer.

Authors:  Kaiyuan Deng; Xiaoqiang Guo; Hao Wang; Jiazeng Xia
Journal:  Tumour Biol       Date:  2014-08-20

7.  A new insight into cancer stem cell markers: Could local and circulating cancer stem cell markers correlate in colorectal cancer?

Authors:  Alireza Mirzaei; Gholamreza Tavoosidana; Afshin Abdi Rad; Farhad Rezaei; Masoumeh Tavakoli-Yaraki; Azade Amini Kadijani; Ehsan Khalili; Zahra Madjd
Journal:  Tumour Biol       Date:  2015-09-17

8.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

9.  MiR-339 and especially miR-766 reactivate the expression of tumor suppressor genes in colorectal cancer cell lines through DNA methyltransferase 3B gene inhibition.

Authors:  Ali Afgar; Pezhman Fard-Esfahani; Amirhosein Mehrtash; Kayhan Azadmanesh; Farnaz Khodarahmi; Mahdis Ghadir; Ladan Teimoori-Toolabi
Journal:  Cancer Biol Ther       Date:  2016-09-26       Impact factor: 4.742

10.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.